169 related articles for article (PubMed ID: 28692379)
61. Caveolin-1 is regulated by c-myc and suppresses c-myc-induced apoptosis.
Timme TL; Goltsov A; Tahir S; Li L; Wang J; Ren C; Johnston RN; Thompson TC
Oncogene; 2000 Jul; 19(29):3256-65. PubMed ID: 10918582
[TBL] [Abstract][Full Text] [Related]
62. ANP32B inhibition suppresses the growth of prostate cancer cells by regulating c-Myc signaling.
Zhou C; Ma H; Yu W; Zhou Y; Zhang X; Meng Y; Chen C; Zhang J; Shi G
Biochem Biophys Res Commun; 2024 Feb; 698():149543. PubMed ID: 38266312
[TBL] [Abstract][Full Text] [Related]
63. SIRT3 inhibits prostate cancer by destabilizing oncoprotein c-MYC through regulation of the PI3K/Akt pathway.
Quan Y; Wang N; Chen Q; Xu J; Cheng W; Di M; Xia W; Gao WQ
Oncotarget; 2015 Sep; 6(28):26494-507. PubMed ID: 26317998
[TBL] [Abstract][Full Text] [Related]
64. O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells.
Itkonen HM; Minner S; Guldvik IJ; Sandmann MJ; Tsourlakis MC; Berge V; Svindland A; Schlomm T; Mills IG
Cancer Res; 2013 Aug; 73(16):5277-87. PubMed ID: 23720054
[TBL] [Abstract][Full Text] [Related]
65. Synthesis and biological evaluation of some novel triazole hybrids of curcumin mimics and their selective anticancer activity against breast and prostate cancer cell lines.
Mandalapu D; Saini KS; Gupta S; Sharma V; Yaseen Malik M; Chaturvedi S; Bala V; Hamidullah ; Thakur S; Maikhuri JP; Wahajuddin M; Konwar R; Gupta G; Sharma VL
Bioorg Med Chem Lett; 2016 Sep; 26(17):4223-32. PubMed ID: 27496212
[TBL] [Abstract][Full Text] [Related]
66. Defects in p21WAF1/CIP1, Rb, and c-myc signaling in phorbol ester-resistant cancer cells.
Blagosklonny MV; Prabhu NS; El-Deiry WS
Cancer Res; 1997 Jan; 57(2):320-5. PubMed ID: 9000576
[TBL] [Abstract][Full Text] [Related]
67. A regulatory circuit HP1γ/miR-451a/c-Myc promotes prostate cancer progression.
Chang C; Liu J; He W; Qu M; Huang X; Deng Y; Shen L; Zhao X; Guo H; Jiang J; Fu XY; Huang R; Zhang D; Yan J
Oncogene; 2018 Jan; 37(4):415-426. PubMed ID: 28967902
[TBL] [Abstract][Full Text] [Related]
68. Conversion of androgen receptor signaling from a growth suppressor in normal prostate epithelial cells to an oncogene in prostate cancer cells involves a gain of function in c-Myc regulation.
Vander Griend DJ; Litvinov IV; Isaacs JT
Int J Biol Sci; 2014; 10(6):627-42. PubMed ID: 24948876
[TBL] [Abstract][Full Text] [Related]
69. MYC is activated by USP2a-mediated modulation of microRNAs in prostate cancer.
Benassi B; Flavin R; Marchionni L; Zanata S; Pan Y; Chowdhury D; Marani M; Strano S; Muti P; Blandino G; Loda M
Cancer Discov; 2012 Mar; 2(3):236-47. PubMed ID: 22585994
[TBL] [Abstract][Full Text] [Related]
70. Histone deacetylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation.
Seo SK; Jin HO; Woo SH; Kim YS; An S; Lee JH; Hong SI; Lee KH; Choe TB; Park IC
J Thorac Oncol; 2011 Aug; 6(8):1313-9. PubMed ID: 21642861
[TBL] [Abstract][Full Text] [Related]
71. Nitroxide tempo, a small molecule, induces apoptosis in prostate carcinoma cells and suppresses tumor growth in athymic mice.
Suy S; Mitchell JB; Samuni A; Mueller S; Kasid U
Cancer; 2005 Mar; 103(6):1302-13. PubMed ID: 15685617
[TBL] [Abstract][Full Text] [Related]
72. Suppression of human prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis.
Aranha O; Grignon R; Fernandes N; McDonnell TJ; Wood DP; Sarkar FH
Int J Oncol; 2003 Apr; 22(4):787-94. PubMed ID: 12632069
[TBL] [Abstract][Full Text] [Related]
73. Scoparone exerts anti-tumor activity against DU145 prostate cancer cells via inhibition of STAT3 activity.
Kim JK; Kim JY; Kim HJ; Park KG; Harris RA; Cho WJ; Lee JT; Lee IK
PLoS One; 2013; 8(11):e80391. PubMed ID: 24260381
[TBL] [Abstract][Full Text] [Related]
74. Receptor-interacting protein kinase 2 (RIPK2) stabilizes c-Myc and is a therapeutic target in prostate cancer metastasis.
Yan Y; Zhou B; Qian C; Vasquez A; Kamra M; Chatterjee A; Lee YJ; Yuan X; Ellis L; Di Vizio D; Posadas EM; Kyprianou N; Knudsen BS; Shah K; Murali R; Gertych A; You S; Freeman MR; Yang W
Nat Commun; 2022 Feb; 13(1):669. PubMed ID: 35115556
[TBL] [Abstract][Full Text] [Related]
75. MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer.
Baena-Del Valle JA; Zheng Q; Esopi DM; Rubenstein M; Hubbard GK; Moncaliano MC; Hruszkewycz A; Vaghasia A; Yegnasubramanian S; Wheelan SJ; Meeker AK; Heaphy CM; Graham MK; De Marzo AM
J Pathol; 2018 Jan; 244(1):11-24. PubMed ID: 28888037
[TBL] [Abstract][Full Text] [Related]
76. Liver X receptor activation inhibits PC-3 prostate cancer cells via the beta-catenin pathway.
Youlin K; Li Z; Weiyang H; Jian K; Siming L; Xin G
Pathol Res Pract; 2017 Mar; 213(3):267-270. PubMed ID: 28139275
[TBL] [Abstract][Full Text] [Related]
77. Transcription factor FoxM1 is the downstream target of c-Myc and contributes to the development of prostate cancer.
Pan H; Zhu Y; Wei W; Shao S; Rui X
World J Surg Oncol; 2018 Mar; 16(1):59. PubMed ID: 29554906
[TBL] [Abstract][Full Text] [Related]
78. TSA suppresses miR-106b-93-25 cluster expression through downregulation of MYC and inhibits proliferation and induces apoptosis in human EMC.
Zhao ZN; Bai JX; Zhou Q; Yan B; Qin WW; Jia LT; Meng YL; Jin BQ; Yao LB; Wang T; Yang AG
PLoS One; 2012; 7(9):e45133. PubMed ID: 23028803
[TBL] [Abstract][Full Text] [Related]
79. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.
Marampon F; Ciccarelli C; Zani BM
Mol Cancer; 2006 Aug; 5():31. PubMed ID: 16899113
[TBL] [Abstract][Full Text] [Related]
80. Role of c-myc protein in hormone refractory prostate carcinoma: cellular response to paclitaxel.
Cassinelli G; Supino R; Zuco V; Lanzi C; Scovassi AI; Semple SC; Zunino F
Biochem Pharmacol; 2004 Sep; 68(5):923-31. PubMed ID: 15294455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
